

# Annual Report Analysis of Listed Vitamin Companies in China/data publication

<https://marketpublishers.com/r/A0E99932A92EN.html>

Date: December 2014

Pages: 34

Price: US\$ 2,160.00 (Single User License)

ID: A0E99932A92EN

## Abstracts

Vitamin industry hot topics in 2014:

On 19 March, 2014, BASF released a statement that its citral production line in Germany plant suffered a fire and had to close down. BASF's total citral capacity accounts for more than 60% of the global capacity, thus the fire leads to the tight supply of citral and has a huge impact on the downstream of vitamin A, fragrance and flavor, vitamin E and other products. Though BASF's citral resumed production in April, domestic supply situation didn't change.

On 11 July, 2014, DSM announced that it had reached an agreement to acquire Aland Nutraceutical Holding, Ltd., a leading producer of vitamin C in China. Through the acquisitions, DSM can further strengthen its status in vitamin C market and expand its domains all over the world of human nutrition and health care, animal nutrition and health care and personal care.

On 29 September, 2014, Zhejiang Hangzhou Xinfu Pharmaceutical Co., Ltd. announced that Hefei Yifan Bio-Pharm Co., Ltd., a subsidiary of Xinfu Pharmaceutical, will merge with Hefei Yifan Pharmaceutical Co., Ltd., another subsidiary of Xinfu Pharmaceutical. After the completion of the merger, Yifan Bio-Pharm will continue to exist while Yifan Pharmaceutical will be dismissed and deregistered.

On 5 Nov., 2014, Guangzhou Lonza (Nansha) Co., Ltd. launched a 15,000 t/a vitamin B3 (niacinamide) and formally put into operation, which further enlarged the production capacity of China's vitamin B3. It's estimated that there is a risk of excess capacity.

### Purpose of report:

To clearly describe China's vitamin industry, CCM has collected lots of information in various ways. In this report, development situation of vitamin listed companies has been described in detail, including company profile, financial performance, product mix, market share, and investment opportunity.

What to report: In this report, the 9 listed vitamin companies have been analyzed exhaustively from the following aspects:

Revenue and net profit of the listed vitamin companies, 2009-2013;

Main product structure of the listed vitamin companies by main business revenue, 2013;

Revenue and gross profit margin of vitamin business of the listed vitamin companies, 2009-2013;

Regional distribution of the listed vitamin companies by main business revenue, 2012 and 2013;

Top 5 customers of the listed vitamin companies by total revenue, 2012 and 2013.

R&D investment of the listed vitamin companies, 2012 and 2013

### Forecasts:

In the next few years, the vitamin industry in China will continue to be promising. On the whole, it's worth investing in it.

## Contents

### **1 OVERVIEW**

### **2 RANKING OF THE 9 LISTED VITAMIN COMPANIES IN CHINA**

- 2.1 Geographic distribution of listed vitamin companies in China
- 2.2 Revenue
- 2.3 Profit
- 2.4 Total assets
- 2.5 R&D investment

### **3 ANALYSIS OF LISTED VITAMIN COMPANIES**

- 3.1 North China Pharmaceutical Co., Ltd.
- 3.2 Zhejiang Medicine Co., Ltd.
- 3.3 Zhejiang NHU Company Ltd.
- 3.4 Northeast Pharmaceutical Group Co., Ltd.
- 3.5 PKU HealthCare Corp., Ltd.
- 3.6 Brother Enterprises Holding Co., Ltd.
- 3.7 Zhejiang Hangzhou Xinfu Pharmaceutical Co., Ltd.
- 3.8 Xiamen Kingdomway Group Company
- 3.9 Hubei Guangji Pharmaceutical Co., Ltd.

### **4 CONCLUSIONS**

## List Of Tables

### LIST OF TABLES

Table 2.1 -1 Basic information of listed vitamin companies in China

Table 2.2-1 Revenue of the 9 listed vitamin companies in China, 2012 and 2013

Table 2.3-1 Net profit of 9 listed vitamin companies in China, 2013

Table 2.4-1 Total assets of 9 listed vitamin companies in China, 2012 and 2013

Table 2.5-1 R&D investment of nine listed vitamin enterprises in China, 2012 and 2013

Table 3.1 -1 Regional distribution of North China Pharmaceutical by main business revenue,2012 and 2013

Table 3.1 -2 Top 5 customers of North China Pharmaceutical by revenue, 2012 and 2013

Table 3.1 -3 R&D investment of North China Pharmaceutical, 2012 and 2013

Table 3.2-1 Regional distribution of Zhejiang Medicine by main business revenue,2012 and 2013

Table 3.2-2 Top 5 customers of Zhejiang Medicine by revenue, 2013

Table 3.2-3 R&D investment of Zhejiang Medicine, 2011-2013

Table 3.3-1 Regional distribution of NHU by main business revenue, 2012 and 2013

Table 3.3-2 Top 5 customers of NHU by revenue, 2012 and 2013

Table 3.3-3 R&D investment of NHU, 2011-2013

Table 3.4-1 Regional distribution of Northeast Pharmaceutical by main business revenue,2012 and 2013

Table 3.4-2 Top 5 customers of Northeast Pharmaceutical by revenue, 2012 and 2013

Table 3.4-3 R&D investment of Northeast Pharmaceutical, 2012 and 2013

Table 3.5-1 Regional distribution of PKU HealthCare by main business revenue,2012 and 2013

Table 3.5-2 Top 5 customers of PKU HealthCare by revenue, 2012 and 2013

Table 3.5-3 R&D investment of PKU HealthCare, 2012 and 2013

Table 3.6-1 Regional distribution of Brother Enterprises by main business revenue,2012 and 2013

Table 3.6-2 Top 5 customers of Brother Enterprises by revenue,2012 and 2013

Table 3.6-3 R&D investment of Brother Enterprises,2012 and 2013

Table 3.7-1 Regional distribution of Xinfu Pharmaceutical by main business revenue,2012 and 2013

Table 3.7-2 Top 5 customers of Xinfu Pharmaceutical by revenue,2012 and 2013

Table 3.7-3 R&D investment of Xinfu Pharmaceutical,2012 and 2013

Table 3.8-1 Regional distribution of Xiamen Kingdomway by main business revenue,2012 and 2013

Table 3.8-2 Top 5 customers of Xiamen Kingdomway by revenue, 2012 and 2013

Table 3.8-3 R&D investment of Xiamen Kingdomway, 2011 -2013

Table 3.9-1 Regional distribution of Guangji Pharmaceutical by main business revenue,2012 and 2013

Table 3.9-2 Top 5 customers of Guangji Pharmaceutical by revenue,2012 and 2013

Table 3.9-3 R&D investment of Guangji Pharmaceutical,2012 and 2013

## List Of Figures

### LIST OF FIGURES

Figure 2.1 -1 Geographic distribution of listed vitamin companies in China,2013

Figure 3.1 -1 Revenue and net profit of North China Pharmaceutical,2009-2013

Figure 3.1 -2 Revenue and gross profit margin of vitamin business of North China Pharmaceutical,2009-2013

Figure 3.1 -3 Product structure of North China Pharmaceutical by main business revenue,2013

Figure 3.2-1 Revenue and net profit of Zhejiang Medicine, 2009-2013

Figure 3.2-2 Revenue and gross profit margin of nutrition business of Zhejiang Medicine,2009-2013

Figure 3.2-3 Product structure of Zhejiang Medicine by main business revenue,2013

Figure 3.3-1 Total revenue and net profit of NHU,2009-2013

Figure 3.3-2 Revenue and gross profit margin of nutrition business of NHU,2009-2013

Figure 3.3-3 Product structure of NHU by main business revenue, 2013

Figure 3.4-1 Total revenue and net profit of Northeast Pharmaceutical, 2009-2013

Figure 3.4-2 Revenue and gross profit margin of API business of Northeast Pharmaceutical,2009-2013

Figure 3.4-3 Product structure of Northeast Pharmaceutical by main business revenue,2013

Figure 3.5-1 Revenue and net profit of PKU HealthCare,2009-2013

Figure 3.5-2 Revenue and gross profit margin of API business of PKU HealthCare,2009-2013

Figure 3.5-3 Product structure of PKU HealthCare by main business revenue,2013

Figure 3.6-1 Total revenue and net profit of Brother Enterprises, 2011 -2013

Figure 3.6-2 Revenue and gross profit margin of vitamin business of Brother Enterprises,2011-2013

Figure 3.6-3 Product structure of Brother Enterprises by main business revenue,2013

Figure 3.7-1 Total revenue and net profit of Xinfu Pharmaceutical, 2009-2013

Figure 3.7-2 Revenue and gross profit margin of vitamin business of Xinfu Pharmaceutical,2009-2013

Figure 3.7-3 Product structure of Xinfu Pharmaceutical by main business revenue, 2013

Figure 3.8-1 Total revenue and net profit of Xiamen Kingdomway, 2011-2013

Figure 3.8-2 Revenue and gross profit margin of vitamin business of Xiamen Kingdomway,2011-2013

Figure 3.8-3 Product structure of Xiamen Kingdomway by main business revenue,2013

Figure 3.9-1 Total revenue and net profit of Guangji Pharmaceutical,2009-2013

Figure 3.9-2 Revenue and gross profit margin of API business of Guangji Pharmaceutical, 2009-2013

Figure 3.9-3 Product structure of Guangji Pharmaceutical by main business revenue, 2013

## **COMPANIES MENTIONED**

North China Pharmaceutical Co., Ltd.

Zhejiang Medicine Co., Ltd.

Zhejiang NHU Company Ltd.

Northeast Pharmaceutical Group Co., Ltd.

PKU HealthCare Corp., Ltd.

Brother Enterprises Holding Co., Ltd.

Zhejiang Hangzhou Xinfu Pharmaceutical Co., Ltd.

Xiamen Kingdomway Group Company

Hubei Guangji Pharmaceutical Co., Ltd.

## I would like to order

Product name: Annual Report Analysis of Listed Vitamin Companies in China/data publication

Product link: <https://marketpublishers.com/r/A0E99932A92EN.html>

Price: US\$ 2,160.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A0E99932A92EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970